Trial Profile
Phase I trial of an orally available ubiquitin protein ligase inhibitor as a potential therapy for cancer.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2015
Price :
$35
*
At a glance
- Drugs Ubiquitin-protein ligase inhibitors (Primary)
- Indications Cancer
- Focus Adverse reactions; First in man
- Sponsors Daiichi Sankyo Company
- 21 Jan 2015 New trial record